{
    "clinical_study": {
        "@rank": "144661", 
        "acronym": "Squarex", 
        "arm_group": [
            {
                "arm_group_label": "0.2% Squaric Acid", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "0.5% Squaric Acid", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo Solution", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Subjects with a history of recurrent herpes labialis will be sensitized with either 2% SADBE\n      or placebo. Following this, subjects sensitized with 2% SADBE will received.2% sqauric acid\n      or.5% squaric acid on their cold sore within 72 hours of a recurrence. Subjects sensitized\n      with placebo solution will receive placebo solution on their cold sore within 72 hours of a\n      recurrence. Subjects will be followed for up to 6 mos after application of study medication."
        }, 
        "brief_title": "Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Herpes Labialis", 
        "condition_browse": {
            "mesh_term": "Herpes Labialis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18\n\n          -  With clinical diagnosis of herpes labialis.\n\n          -  who self report having six or more episodes of herpes labialis in the previous 12\n             months.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females.\n\n          -  Current or recurrent infection or any underlying condition that may predispose to\n             infection or anyone who has been admitted to the hospital due to bacteremia,\n             pneumonia or any other serious infection.\n\n          -  Therapy with glucocorticoid or immunosuppressant at time of recruitment or within\n             past 4 weeks, except for inhaled corticosteroids for asthma.\n\n          -  History of malignancy (except patients with surgically cured basal cell or squamous\n             cell skin cancers who will be eligible)\n\n          -  History of organ transplantation\n\n          -  Negative HIV-positive status determined by history at screening or known history of\n             any other immuno-suppressing disease.\n\n          -  Severe comorbidities (diabetes mellitus requiring insulin, CHF (EF<50% at baseline\n             will be exclusionary) of any severity, MI, CVA or TIA within 3 months of screening\n             visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease\n\n          -  Subject is currently enrolled in another investigational device or drug trial(s), or\n             subject has received other investigational agent(s) within 28 days of baseline visit.\n\n          -  Subjects who have known hypersensitivity to Squaric acid or any of its components.\n\n          -  History of recent alcohol or substance abuse (< 1 year)\n\n          -  Any condition judged by the investigator to cause this clinical trial to be\n             detrimental to the patient.\n\n          -  History of psychiatric disease that would interfere with the patient's ability to\n             comply with the study protocol\n\n          -  History of non-compliance with other therapies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971385", 
            "org_study_id": "2013P001028"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.2% Squaric Acid", 
                    "0.5% Squaric Acid"
                ], 
                "intervention_name": "Squaric Acid solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Squaric Acid Dibutyl Ester solution", 
                    "SADBE"
                ]
            }, 
            {
                "arm_group_label": "Placebo Solution", 
                "intervention_name": "Placebo solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Squaric acid dibutyl ester"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "contact": {
                "email": "harvardskinstudies@partners.org", 
                "last_name": "Lynne Hermosilla", 
                "phone": "617-726-5066"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Alexandra B Kimball, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Clinical Trial to Test the Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis", 
        "overall_contact": {
            "email": "harvardskinstudies@partners.org", 
            "last_name": "Alexandra B Kimball, MD", 
            "phone": "6177265066"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Alexandra B Kimball, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the effect of squaric acid on frequency and severity of herpes labialis outbreaks compared to placebo in terms of number of days with lesions during the 8 months after the last treatment.", 
            "measure": "Number of days with lesions", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971385"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Alexandra Kimball", 
            "investigator_title": "Director, Clinical Unit for Research Trials in Skin", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the effect of squaric acid on frequency and severity of herpes labialis outbreaks compared to placebo in terms of number of days until first subject-reported recurrence (distinct new outbreak) after the last treatment.", 
                "measure": "Number of days until first subject-reported recurrence.", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "To assess the safety and tolerability of squaric acid solution the number of adverse events in each treatment arm will be collected and compared.", 
                "measure": "Number of adverse events reported", 
                "safety_issue": "Yes", 
                "time_frame": "8 months"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}